A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies

Tan, A. R., Chan, N., Kiesel, B. F., Stein, M. N., Moss, R. A., Malhotra, J., Aisner, J., Shah, M., Gounder, M., Lin, H., Kane, M. P., Lin, Y., Ji, J., Chen, A., Beumer, J. H., & Mehnert, J. M. (2021). A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. Cancer Chemotherapy and Pharmacology, 89(1), 49–58. https://doi.org/10.1007/s00280-021-04350-x
Authors:
Antoinette R. Tan
Nancy Chan
Brian F. Kiesel
Mark N. Stein
Rebecca A. Moss
Jyoti Malhotra
Joseph Aisner
Mansi Shah
Murugesan Gounder
Hongxia Lin
Michael P. Kane
Yong Lin
Jiuping Ji
Alice Chen
Jan H. Beumer
Janice M. Mehnert
Affiliated Authors:
Mark N. Stein
Author Keywords:
parp inhibitors
pharmacokinetics
phase i study
veliparib
Publication Type:
Article
Unique ID:
10.1007/s00280-021-04350-x
PMID:
Publication Date:
Data Source:
Scopus

Record Created: